RxDoctor Payments Data

Meredith Hawkins Pridgeon, DO

Internal Medicine · Granbury, TXNPI 1184086191

Payments from drug & device makers

$4,959in general payments, 2019–2025

Across 285 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$561
  • Amarin Pharma, Inc.$382
  • AbbVie$336
  • Exact Sciences$285
  • AstraZeneca$243
  • Novo Nordisk$240
  • plus $3K from 46 others

What the payments were for

  • Food & beverage$4,959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,959 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$141,284
Medicare patients
383
Services billed
3,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide151$206,004
EliquisApixaban112$140,062
MounjaroTirzepatide42$80,102
JardianceEmpagliflozin44$65,935
TrulicityDulaglutide32$49,301
FarxigaDapagliflozin Propanediol31$41,687
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$36,968
RelistorMethylnaltrexone Bromide15$34,031
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$33,214
MyrbetriqMirabegron33$28,259
LinzessLinaclotide20$27,131
XareltoRivaroxaban17$26,146
RybelsusSemaglutide15$19,068
Humalog Kwikpen U-200Insulin Lispro27$10,938
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$10,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$240$225,072166 claims
PfizerEliquis, Premarin$146$145,435128 claims
Lilly USA, LLCMounjaro, Trulicity$235$129,40374 claims
Boehringer IngelheimJardiance$561$65,93544 claims
AstraZenecaFarxiga, Symbicort$243$48,60554 claims
GSKTrelegy Ellipta$143$36,96833 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$208$34,03115 claims
AbbVieLinzess, Synthroid$336$31,48998 claims
Astellas Pharma US IncMyrbetriq$63$28,25933 claims
Johnson & JohnsonXarelto$192$26,14617 claims
MerckBelsomra$212$5,01711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Granbury

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →